Published in J Clin Psychopharmacol on October 01, 2005
Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin Drug Metab Toxicol (2012) 0.88
More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J (2017) 0.75
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 2.97
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther (2002) 2.01
CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther (2004) 1.99
Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol (2010) 1.96
Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics (2002) 1.75
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther (2002) 1.58
Functional significance of a hereditary adenine insertion variant in the 5'-UTR of the endothelin-1 gene. Pharmacogenetics (2003) 1.51
MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol (2007) 1.45
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother (2005) 1.42
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2004) 1.42
Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.40
CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis (2003) 1.28
The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther (2002) 1.23
CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis (2002) 1.23
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol (2003) 1.20
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics (2008) 1.18
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry (2010) 1.16
Educating European (junior) doctors for safe prescribing. Basic Clin Pharmacol Toxicol (2007) 1.15
Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos (2005) 1.14
CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer (2003) 1.13
Gender differences in the performance of a computerized version of the alcohol use disorders identification test in subcritically injured patients who are admitted to the emergency department. Alcohol Clin Exp Res (2004) 1.12
The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. J Histochem Cytochem (2005) 1.10
Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther (2004) 1.05
[Hypoglycemic risk of insulinotropic drugs]. Med Monatsschr Pharm (2009) 1.05
Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control (2003) 1.04
A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.04
Event-related potentials associated with Attention Network Test. Int J Psychophysiol (2010) 1.03
Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS One (2011) 1.02
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics (2009) 1.02
Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol Pharmacol (2011) 1.01
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol (2002) 0.99
Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther (2006) 0.99
miRNAs as mediators of drug resistance. Epigenomics (2012) 0.98
Pregabalin versus pramipexole for restless legs syndrome. N Engl J Med (2014) 0.96
Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics (2008) 0.95
Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med (2007) 0.94
Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. Mutat Res (2005) 0.94
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol (2014) 0.94
Selective anterior cingulate cortex deficit during conflict solution in schizophrenia: an event-related potential study. J Psychiatr Res (2006) 0.93
High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma. Cancer Lett (2004) 0.91
Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am J Pathol (2003) 0.90
Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics (2004) 0.90
Executive attention in schizophrenic males and the impact of COMT Val108/158Met genotype on performance on the attention network test. Schizophr Bull (2008) 0.90
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. Eur J Clin Pharmacol (2011) 0.90
MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics (2012) 0.90
OpenVigil--free eyeballs on AERS pharmacovigilance data. Nat Biotechnol (2012) 0.90
Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. Int J Cancer (2004) 0.89
Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem (2002) 0.89
Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus. Ther Drug Monit (2015) 0.89
Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. BMC Cancer (2013) 0.89
Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics (2010) 0.88
Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol (2004) 0.87
Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. Vet Res (2011) 0.86
Attention Network Test reveals alerting network dysfunction in multiple sclerosis. Mult Scler (2009) 0.86
Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology (2004) 0.85
Endothelial NO synthase polymorphisms and postural tachycardia syndrome. Hypertension (2005) 0.85
Evidence of specificity of a visual P3 amplitude modulation deficit in schizophrenia. Schizophr Res (2010) 0.85
Endothelial nitric oxide synthase Glu(298)-->Asp polymorphism, carotid atherosclerosis and intima-media thickness in a general population sample. Clin Sci (Lond) (2005) 0.84
Single-subject classification of schizophrenia by event-related potentials during selective attention. Neuroimage (2010) 0.84
Attention network test (ANT) reveals gender-specific alterations of executive function in schizophrenia. Psychiatry Res (2009) 0.84
Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med (2014) 0.84
MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol (2014) 0.83
Identification and functional analysis of genetic variants of the human beta-glucuronidase in a German population sample. Pharmacogenet Genomics (2005) 0.83
Effects of smoking history on selective attention in schizophrenia. Neuropharmacology (2012) 0.82
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol (2010) 0.82
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol (2006) 0.82
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res (2013) 0.82
Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev (2004) 0.81
Eosinophilia indicating subclinical clozapine-induced pericarditis. J Clin Psychiatry (2007) 0.81
Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics (2009) 0.81
Differential expression and functionality of TRPA1 protein genetic variants in conditions of thermal stimulation. J Biol Chem (2012) 0.81
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics (2002) 0.81
Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics (2011) 0.81
Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method. Chem Biol Interact (2011) 0.81
Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. J Hypertens (2005) 0.80
Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. Pharmacogenomics (2011) 0.80
'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. Cancer Lett (2005) 0.80
Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes. Pharmacogenet Genomics (2007) 0.79
Test-retest reliability of Attention Network Test measures in schizophrenia. Schizophr Res (2011) 0.79
Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. Clin Ther (2010) 0.79
HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics (2016) 0.79
Dissection of early bottom-up and top-down deficits during visual attention in schizophrenia. Clin Neurophysiol (2010) 0.79
Smoking reduces language lateralization: a dichotic listening study with control participants and schizophrenia patients. Brain Cogn (2011) 0.79
Association between the N-acetylation genetic polymorphism and bronchial asthma. Br J Clin Pharmacol (2002) 0.79
Smoking improves divided attention in schizophrenia. Psychopharmacology (Berl) (2014) 0.79
The promises of personalized medicine. Eur J Clin Pharmacol (2010) 0.78
Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379. Pharmacogenet Genomics (2014) 0.78
Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther (2002) 0.78
Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia (2008) 0.78
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis (2010) 0.77
Influence of an insertion variant in the 5'UTR of the endothelin-1 gene on orthostatic intolerance. Am J Med Sci (2005) 0.77
Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma. Eur J Clin Pharmacol (2003) 0.77
Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver Int (2006) 0.76
Spatiotemporal mapping of sex differences during attentional processing. Hum Brain Mapp (2009) 0.76
Conference Scene: Pharmacogenomics at the second PharmSciFair 2009: adverse drug reactions and clinical implementation. Pharmacogenomics (2009) 0.76